Anti-PD-1 therapies—a new first-line option in advanced melanoma

被引：0
|
作者：
Ryan J. Sullivan
Keith T. Flaherty
机构：
[1] Massachusetts General Hospital Cancer Center,Department of Medicine
来源：
Nature Reviews Clinical Oncology | 2015年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment with pembrolizumab, an anti-PD-1 antibody, improved progression-free survival compared with investigator-choice chemotherapy in a phase II trial in patients with advanced-stage melanoma previously treated with ipilimumab. Two subsequent independent trials have confirmed that anti-PD-1 therapy is a better option than either chemotherapy or ipilimumab in the frontline setting.
引用
收藏
页码：625 / 626
页数：1
相关论文
共 50 条
  • [21] Clinical biomarkers of response to anti-PD-1 first-line treatment in an Italian patient cohort
    Di Pietro, Francesca Romana
    Verkhovskaia, Sofia
    Mastroeni, Simona
    Carbone, Maria Luigia
    Abeni, Damiano
    Di Rocco, Zorika Christiana
    Sama, Nicola
    Zappala, Albina Rita
    Marchetti, Paolo
    De Galitiis, Federica
    Failla, Cristina Maria
    Fortes, Cristina
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (SUPPL 1)
  • [22] Anti-PD-1 combination regimen as first-line therapy in advanced biliary tract cancer and biomarker exploration: A retrospective study
    Guo, Jingyi
    Zhou, Qun
    Zhou, Mingzhen
    Dai, Hengheng
    Li, Lin
    Liu, Baorui
    Shen, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era
    Lamba, Nayan
    Ott, Patrick A.
    Iorgulescu, J. Bryan
    JAMA NETWORK OPEN, 2022, 5 (08) : E2225459
  • [24] Anti-PD-1 Therapy in Melanoma
    Moreno, Blanca Hornet
    Parisi, Giulia
    Robert, Lidia
    Ribas, Anton
    SEMINARS IN ONCOLOGY, 2015, 42 (03) : 466 - 473
  • [25] Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma
    Aya, Francisco
    Gaba, Lydia
    Victoria, Ivan
    Fernandez-Martinez, Aranzazu
    Tosca, Monica
    Prat, Aleix
    Arance, Ana
    FUTURE ONCOLOGY, 2016, 12 (23) : 2683 - 2688
  • [26] Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer
    Fan, Y.
    Xu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2149 - S2150
  • [27] Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
    Sahni, Sakshi
    Valecha, Gautam
    Sahni, Ankit
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2018, 10 (12)
  • [28] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Babacan, Nalan Akgul
    Eroglu, Zeynep
    CURRENT ONCOLOGY REPORTS, 2020, 22 (04)
  • [29] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Nalan Akgul Babacan
    Zeynep Eroglu
    Current Oncology Reports, 2020, 22
  • [30] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
    van Breeschoten, Jesper
    Wouters, Michel W. J. M.
    Hilarius, Doranne L.
    Haanen, John B.
    Blank, Christian U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    de Groot, Jan-Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Piersma, Djura
    van Rijn, Roos S.
    Suijkerbuijk, Karijn P. M.
    Blokx, Willeke A. M.
    Tije, Bert-Jan J. ten
    Veldt, Astrid A. M. van der
    Vreugdenhil, Art
    Boers-Sonderen, Marye J.
    van den Eertwegh, Alfonsus J. M.
    BRITISH JOURNAL OF CANCER, 2021, 124 (07) : 1222 - 1230
12345